Abstract
This study was designed to develop innovative degradable hydroxyapatite (HAp)-based systems working as potential carriers for low-dose drugs. The HAp-based systems combine three components: HAp, sodium silicate and citric acid (HSC), which together could exhibit optimal characteristics as drug carriers. Both synthetic HAp (s-HAp) and extracted biological HAp (b-HAp) were used as sources of HAp due to their optimal biological properties and adsorption capacity. The s-HAp powder was prepared by co-precipitation method, while the b-HAp powder was extracted from bovine bone. Aqueous drug solutions of the atenolol, antihypertensive drug, were used as a model drug to investigate the drug release behaviour from HSC composites. The properties of s-HAP, b-HAp powders and HSC composite tablets were characterized by conventional methods. The results revealed that both s-HAp and b-HAp are pure powders and exhibited agglomerated microstructures with grain sizes less than 100 μm. The HSC composite tablets exhibited a dense structure, excellent compressive strength and excellent in-vitro release behaviour of atenolol. The results indicated that HAp powders and their composite tablets can be promised as economic raw materials and carriers for low-dose drugs.
Similar content being viewed by others
References
Habraken W J E M, Wolke J G C and Jansen J A 2007 Adv. Drug Deliver. Rev. 59 234
Zheng J 2009 Formulation and analytical development for low-dose oral drug products (New Jersey: John Wiley & Sons Inc.)
Lakshmanan S, Gupta G K, Avci P, Chandran R, Sadasivam M, Elisa A et al 2014, Adv. Drug Deliver. Rev. 71 98
Zhou H and Lee J 2011 Acta Biomater. 7 2769
Betsiou M, Bantsis G, Zoi I and Sikalidis C 2012 Ceram. Int. 38 2719
Ginebra M P, Canal C, Espanol M, Pastorino D and Montufar E B 2012 Adv. Drug Deliver. Rev. 64 1090
Öner M, Yetiz E, Ay V and Uysal U 2011 Ceram. Int. 37 2117
Cosijns A, Vervaet C, Luyten J, Mullens S, Siepmann F, Van Hoorebeke L et al 2007, Eur. J. Pharm. Biopharm. 67 498
Alexa I F, Ignat M, Popovici R F, Timpu D and Popovici E 2012 Int. J. Pharm. 436 111
Sadat-Shojai M, Khorasani M T, Dinpanah-Khoshdargi E and Jamshidi A 2013 Acta Biomater. 9 7591
Barakat N A M, Khalil K A, Sheikh F A, Omran A M, Gaihre B, Khil S M and Kim H Y 2008 Mater. Sci. Eng. C 28 1381
Netz D J A, Sepulveda P, Pandolfelli V C, Spadaro A C C, Alencastre J B, Bentley M V L B and Marchetti J M 2001 Int. J. Pharm. 213 117
Son J S, Appleford M, Ong J L, Wenke J C, Kim J M, Choi S H and Oh D S 2011 J. Control. Release 153 133
Vernon B 2011 Injectable biomaterials: science and applications (Cambridge, UK: Woodhead Publishing Limited)
Rahaman M N 2003 Ceramic processing and sintering (New York: Marcel Dekker Inc.) 2nd edn
Miyaji F, Kim H -M, Handa S and Kokubo T 1999 Biomaterials 20 913
Oliveira A L, Malafaya P B and Reis R L 2003 Biomaterials 24 2575
Gottschalck T E and McEwen G N 2004 International cosmetic ingredient dictionary and handbook (Washington DC: CTFA) 10th ed., Vol. 1–4
Jurkić L M, Cepanec I, Pavelić S K and Pavelić K 2013 Nutr. Metab. 10 2
Liang W, Tu Y, Zhou H, Liu C and Rüssel C 2011 J. Non-Cryst. Solids 357 958
Shoghi E, Fuguet E, Bosch E and Ràfols C 2013 Eur. J. Pharm. Sci. 48 291
Siepe S, Lueckel B, Kramer A, Ries A and Gurny R 2006 Int. J. Pharm. 316 14
Tatavarti A S and Hoag S W 2006 J. Pharm. Sci. 95 1459
Nykänen P, Lempää S, Aaltonena M L, Jürjenson H, Veski P and Marvola M 2001 Int. J. Pharm. 229 155
Peppas N A 1985 Pharm. Acta Helv. 60 110
Korsmeyer R W, Gurny R, Doelker E, Buri P and Peppas N A 1983 Int. J. Pharm. 15 25
Morsy R, Elsayed M, Krause-Rehberg R, Dlubek G and Elnimr T 2010 J. Eur. Ceram. Soc. 30 1897
Boutinguiza M, Pou J, Comesaña R, Lusquiños F, de Carlos A and León B 2012 Mater. Sci. Eng. C 32 478
Venables H J and Wells J I 2001 Drug Dev. Ind. Pharm. 27 599
Vromans H, Poels-Janssen H G M and Egermann H 1999 Pharm. Dev. Technol. 4 297
Rathbone M I and Gurny R 2000 Controlled release veterinary drug delivery: biological and pharmaceutical considerations (Amsterdam: Elsevier Science)
Saltzman W M 2001 Drug delivery: engineering principles for drug therapy (Oxford: Oxford University Press Inc.)
Maderuelo C, Zarzuelo A and Lanao J M 2011 J. Control. Release 154 2
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
MORSY, R. Development and evaluation of degradable hydroxyapatite/sodium silicate composite for low-dose drug delivery systems. Bull Mater Sci 39, 1273–1278 (2016). https://doi.org/10.1007/s12034-016-1269-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12034-016-1269-9